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Doctors are confronted daily with the results of new trials
evaluating drugs. Many practitioners are unfamiliar with the
terminology and science underlying intervention studies and
may find it difficult to interpret such studies.
PLACEBO COMPARATIVE STUDIES VERSUS
EQUIVALENCE STUDIES
Until recently most trials have compared placebo with active
treatment, the null hypothesis being that the two forms of
therapy are equal. A P-value < 0.05 is interpreted as rejection of
the null hypothesis, and the conclusion is that active therapy is
superior to placebo.
More frequently, however, active therapy is compared with
active therapy. In this setting, failure to reject the null
hypothesis cannot be interpreted as equivalence. For
equivalence to be demonstrated, a trial designed to show
equivalence is needed. An equivalence study should state the
aim of demonstrating equivalence, much larger numbers of
participants are needed (often four times as many as in a
placebo comparative study), and the analysis should be
handled differently to that of a placebo-controlled trial.!
RANDOMISATION AND ITS CONCEALMENT
The natural history of a disease may lead to a favourable
outcome in some patients but not others. This necessitates
randomisation in order to spread possible extraneous
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prognostic factors evenly among the groups being compared,
provided that the group is large enough.
Adequate concealment of random allocation (e.g. by
ensuring that randomisation cannot be manipulated by seeing
through an envelope) is, however, essential. Studies with
doubtful concealment tend to show a greater treatment effect
(therefore biased) compared with studies with adequate
concealment.'
BLINDING
Blinding is needed to exclude bias. Randomised controlled
trials are often done in a double-blind manner - the patient is
blinded via the addition of placebo and the doctor is blinded
because treatment and placebo are coded in such a manner that
it is impossible to discern between the two. It is not always
possible to blind with therapy as regimens involving more than
one agent may be used. The PROBE design (prospective,
randomised, open with blinded end-point evaluation) is often
used in this instance.' The blinded evaluation of outcome is
therefore a minimum requirement.
Loss OF FOLLOW-UP
The number of patients lost to follow-up should be minimal
and should preferably not be related to either form of
treatment. Exact figures beyond which the validity of the study
is doubtful are not clear. In general, loss of follow-up greater
than 20% makes the results questionable; some journals will




Care between the two groups should be comparable, e.g. same
time schedule and intensity of care. This safeguards patients
benefiting from any intervention other than the one being
studied.
In this instance it means that 5 patients have to be treated in
order to prevent one event.
There is no magical NNT figure above which treatment is
worthwhile or cost effective. This is still left to the judgement
of the physician and will depend on resources available.
INTENTION TO TREAT ANALYSIS
EVALUATING AN ARTICLE ON THERAPY (FIG. 1)
EVALUATING AN ARTICLE ON THERAPY
1. Is the study valid?
a) Study design issues b) Statistical issues
Randomised 0 Adequate power and
Concealment of sample size 0
treatment allocation 0 Equivalence or
Blinded superiority study 0
Single 0 Intention to treat
Double 0 analysis 0
PROBE 0
Baseline comparability 0
Equivalence of care 0
Useful guidelines from McMaster University can be found on
the Internet(http://hiru.hirunet.mcmaster.co/ebm/u~erguid/
default.htm). .
When reading a journal one approach would be:
Question 1. Does the particular disease and its therapy
interest me?
Question 2. Are the results of the study valid (equivalence v.
placebo, randornisation, blinding, comparative care, follow-up,
intention to treat analysis).
Question 3. What is the treatment effect (and the uncertainty




3. Can I apply these results
in my practice?
Do I need special
expertise or resources? 0
Would benefit exceed
possible harm? 0
What will my patient(s)
prefer? 0
o
Are my patient(s) similar? 0
Is their risk similar or
greater?
Oul· RRR ARR NNT
come (95%(1) (95%(1) (95%0)
2. Are the results
statistically and clinically
significant?
Fig. 1. Critical apprai5al worksheet.
In an intervention study the outcome of interest is the
reduction of one or more events (outcomes) and all important
outcomes should be considered. The reader must ascertain if
the outcome represents a hard end-point such as death or
stroke rather than a surrogate end-point such as improvement
in a certain physiological parameter, e.g. lipid level. Risk
reduction can be defined in relative and absolute terms.'
Relative risk reduction (RRR) = risk in control group minus
risk in the active treatment group divided by risk in control
group.
PRECISION AND INTERPRETATION OF RESULTS
Myocardial infarction (MI) rate on placebo 40% and MI rate on
aspirin 20%:
40- 20
(RRR) = -- = 0.5 x 100 = 50%.
40
This risk reduction should be accompanied by a confidence
interval (Cl), which is an estimate of the precision of the risk
reduction. The width of this Cl reflects the sample size and the
degree of uncertainty around this estimate. The RRR of 50%
may seem very impressive; usually a RRR of;;, 25% is clinically
relevant.
Patients should be analysed in the groups that they were
initially randomised to. Failure to do so results in loss of the
randornisation effect, and bias occurs. Many studies report
both an intention to treat analysis and the results for those only
complying with the given treatment.
HYPOTHETICAL EXAMPLE
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The true effect, however, is very much dependent on the
baseline risk. For example, if the MI rate on placebo was 0.4%
and on aspirin 0.2%, then the RRR would still be 50%. The
number of events in this last example is so low that
implementing this therapy on large numbers of people in order
to prevent a rare event is questionable.
~ . The concept of ~bsolute ~isk reduction (ARR) is easier to
. mterpret from a clIrucal pomt of vIew: ARR = nsk in the control
group minus risk in the active treatment group =40% - 20% =
20%. The RRR is 50%, yet the ARR is only 20%. ARR can then
also be translated into a very useful concept; namely numbers
needed to treat (NNT):'
NNT = 1/ARR = 1 10 = 5.
0.2 2
SAMJFoRUM--------~-----,
Question 4. Given these results in a valid study, how
applicable are they to my clinical setting (the profile of my
patients, and their preferences, resources).
The last question is very important. Many practice- and
patient-related factors will determine the ultimate use or non-
use of a certain therapy. Patient preference is a vital component
of evidence-based medicine.' In a study of anti-thrombotic
treatment for atrial fibrillation, 20 out of 100 patients at risk for
thrombo-embolism declined warfarin. Patients declining
warfarin were inclined to seek a higher level of benefit than
those taking it, as measured by the minimal clinically
important difference.'
Keeping up with the medical literature demands critical
appraisal skills of the practising physician. This brief article
and the evaluation worksheet constructed by the authors
(Fig. 1) could aid in developing appraisal of the validity of
interventional studies.
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Roal van Zyl-Smit, Phillip Mills, Louis Vogelpoel
A 40-year-old experienced and well-trained marathon rurmer
attempted his second Comrades Marathon (a 90 km
ultramarathon). He felt perfectly fit and well before the race
and, as was his custom, took one 2 mg loperarnide (lmodium)
tablet before the race as prophylaxis against diarrhoea. During
the course of the race he took 6 paracetamol 500
mg/chlormezanone 100 mg (BessenoJ) tablets for the expected
aches and pains. He completed the race over a period of 9
hours, having taken what appears to have been adequate
volumes of fluids. The discomfort experienced during the race
was similar to that he had experienced during previous races.
On the day following the race he experienced bilateral loin
pain for which he took another 2 Bessenol tablets, and during
the following 5 days he used a total of 11 Stopayne tablets
(paracetamol/ caffeine/ codeine phosphate / meprobamate).
During the entire period following the race he had mild
muscle aches and pains and did not notice any diminution in
urine output.
Nine days after the marathon the patient attended a social
function and was noted to have an elevated jugular venous
pressure by an astute general physician also present at the
function. A medical consultation was arranged for the
following day.
The patient was noted to be generally well but with a blood
pressure of 200/140 mmHg, pulse 60/min, heart clinically
normal, bilateral basal pulmonary crackles and mild tenderness
over both renal angles. His urine contained 2+ protein, 1+
blood and moderate numbers of granular casts. Plasma
creatinine was 713llmol/l, urea 32.7 mrnol/l, potassium 5.5
mmol/l, lactic dehydrogenase (LDH) 568 U /1 (normal range
170 - 350 U /I), alanine aminotransferase (ALT) 159 U /1 (normal
range 1 - 25 U /1), gamma-glutamyltransferase (GGT) 175 U /I
(normal range 0 - 65 U / I), serum calcium 2.3 mrnol/l, inorganic
phosphate 2.08 mmol/I and serum urate 0.68 mmol/l (normal
Roal van Zyl-Smit is a consultant nephrologist at Groote Schuur
Hospital, and has completed two Comrades Marathons. Louis
Vogelpoel is the astute physician who noted the raised venous
pressure in the case described. Philip Mills, the medical registrar
involved in handling the case, is now a consultant cardiologist.
